Ono and Meiji Seika make development and commercialization agreement on Limaprost

29 July 2014

Japanese companies Ono Pharmaceutical (TYO: 4528) and Meiji Seika (TYO: 2202) have announced an agreement on the development and commercialization of Limaprost alfadex, for lumbar spinal canal stenosis.

The agreement is for Meiji to have exclusive rights to develop and commercialize Limaprost in Thailand and Indonesia. Meiji will make an upfront payment and development milestones to Ono, and will develop and sell the drug through local subsidiaries. After the launch in these regions, Meiji will pay royalties and sales milestones to Ono based on achievement of projected sales of Limaprost.

Ono will retain rights to co-promote Limaprost with Meiji in Thailand and Indonesia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK